Laura Alder, MD
@lauraaldermd.bsky.social
Thoracic Medical Oncologist @DukeCancer. Asst Prof @DukeMedicine. Deputy Director Duke Center for Brain and Spine Mets. Passionate about #LCSM 🫁🎯🧬, clinical trials, PROs, #MedEd
Pinned
Laura Alder, MD
@lauraaldermd.bsky.social
· Nov 22
Rising lung cancer cases in nonsmoking women under 50: Experts urge awareness
An unexpected surge in lung cancer cases among nonsmoking women under 50 is raising alarms among oncologists, emphasizing the need for heightened awareness.
www.wral.com
Honored to be interviewed about the rising incidence of lung cancer in non-smokers and especially females on @wral.bsky.social to shed light on #LCSM during #LungCancerAwarenessMonth and highlight the #HearHer campaign
www.wral.com/lifestyle/he...
@younglungcancer.bsky.social
www.wral.com/lifestyle/he...
@younglungcancer.bsky.social
Reposted by Laura Alder, MD
Did you catch the most recent episode of #LungCancerConsidered? @narjustflorezmd.bsky.social & @lauraaldermd.bsky.social dive into lung cancer & brain metastases—why MRI surveillance matters, how to time radiation & balancing risks like radiation necrosis.
🎧 Listen now: bit.ly/TTLC25LC-BM
🎧 Listen now: bit.ly/TTLC25LC-BM
Live from TTLC25: Lung Cancer and Brain Metastasis | IASLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses lung cancer and brain metastasis with Dr. Laura Alder.
bit.ly
March 25, 2025 at 4:01 PM
Did you catch the most recent episode of #LungCancerConsidered? @narjustflorezmd.bsky.social & @lauraaldermd.bsky.social dive into lung cancer & brain metastases—why MRI surveillance matters, how to time radiation & balancing risks like radiation necrosis.
🎧 Listen now: bit.ly/TTLC25LC-BM
🎧 Listen now: bit.ly/TTLC25LC-BM
Reposted by Laura Alder, MD
Mentorship meeting with Dr. @LauraAlderMD in Miami… I can get used to this
Aims 1, 2, and 3 drafted
Up to next !
2025 @precisca Fellows Retreat
Aims 1, 2, and 3 drafted
Up to next !
2025 @precisca Fellows Retreat
March 22, 2025 at 5:33 PM
Mentorship meeting with Dr. @LauraAlderMD in Miami… I can get used to this
Aims 1, 2, and 3 drafted
Up to next !
2025 @precisca Fellows Retreat
Aims 1, 2, and 3 drafted
Up to next !
2025 @precisca Fellows Retreat
Reposted by Laura Alder, MD
Check out the ABC11 interview with @lauraaldermd.bsky.social, our Deputy Medical Director, about lung cancer, new treatments, and the Duke Center for Brain and Spine Metastasis. (Her interview starts at the 4-minute mark!)
abc11.com/post/abc11-t...
abc11.com/post/abc11-t...
ABC11 Together Perspectives for March: Durham Crop Hunger Walk and Walk to Defeat Dementia
ABC11 Together Perspectives for March includes fundraiser for lung cancer research
abc11.com
March 12, 2025 at 3:33 PM
Check out the ABC11 interview with @lauraaldermd.bsky.social, our Deputy Medical Director, about lung cancer, new treatments, and the Duke Center for Brain and Spine Metastasis. (Her interview starts at the 4-minute mark!)
abc11.com/post/abc11-t...
abc11.com/post/abc11-t...
Honored to discuss lung cancer with ABC11 highlighting screening, self-advocacy, destigmatization, and the crucial impact of research on cancer treatments resulting in improved QoL and outcomes. @dukecancer.bsky.social #LCSM #LungCancer #CancerResearch #OncSky
muckrack.com/broadcast/sa...
muckrack.com/broadcast/sa...
Muck Rack | For journalists and public relations
Use Muck Rack to find journalists, get press for your story, monitor the news and report on the impact of your PR. Journalists can build portfolios and accelerate their careers.
muckrack.com
March 12, 2025 at 12:22 AM
Honored to discuss lung cancer with ABC11 highlighting screening, self-advocacy, destigmatization, and the crucial impact of research on cancer treatments resulting in improved QoL and outcomes. @dukecancer.bsky.social #LCSM #LungCancer #CancerResearch #OncSky
muckrack.com/broadcast/sa...
muckrack.com/broadcast/sa...
Reposted by Laura Alder, MD
February 7, 2025 at 9:54 AM
So honored, thankful, and excited to be a part of the 2025 IASLC Academy. Can’t wait to meet the cohort and the mentors, form new connections and collaborations, and learn from such stellar minds!!
@iaslc.bsky.social #LCSM
@iaslc.bsky.social #LCSM
January 14, 2025 at 6:43 PM
So honored, thankful, and excited to be a part of the 2025 IASLC Academy. Can’t wait to meet the cohort and the mentors, form new connections and collaborations, and learn from such stellar minds!!
@iaslc.bsky.social #LCSM
@iaslc.bsky.social #LCSM
Always enjoy these JTO "Controversies in Thoracic Oncology!" This issue's relevant debate of including adjuvant IO after neo-adj chemo/IO raises great points, reviews current data, highlights the unknown.
@drcamidge.bsky.social #LCSM
www.jto.org/article/S155...
www.jto.org/article/S155...
@drcamidge.bsky.social #LCSM
www.jto.org/article/S155...
www.jto.org/article/S155...
January 8, 2025 at 5:16 PM
Always enjoy these JTO "Controversies in Thoracic Oncology!" This issue's relevant debate of including adjuvant IO after neo-adj chemo/IO raises great points, reviews current data, highlights the unknown.
@drcamidge.bsky.social #LCSM
www.jto.org/article/S155...
www.jto.org/article/S155...
@drcamidge.bsky.social #LCSM
www.jto.org/article/S155...
www.jto.org/article/S155...
Excellent review of lung neuroendocrine neoplasms by Dr Sen,
@naglaakarimmd.bsky.social and team! Terrific discussion of molecular landscape, existing therapeutic challenges, and diagnosis & management strategies.
#LCSM #LungNETs #SCLC
@thelancet.bsky.social
www.thelancet.com/journals/lan...
@naglaakarimmd.bsky.social and team! Terrific discussion of molecular landscape, existing therapeutic challenges, and diagnosis & management strategies.
#LCSM #LungNETs #SCLC
@thelancet.bsky.social
www.thelancet.com/journals/lan...
January 7, 2025 at 2:58 AM
Excellent review of lung neuroendocrine neoplasms by Dr Sen,
@naglaakarimmd.bsky.social and team! Terrific discussion of molecular landscape, existing therapeutic challenges, and diagnosis & management strategies.
#LCSM #LungNETs #SCLC
@thelancet.bsky.social
www.thelancet.com/journals/lan...
@naglaakarimmd.bsky.social and team! Terrific discussion of molecular landscape, existing therapeutic challenges, and diagnosis & management strategies.
#LCSM #LungNETs #SCLC
@thelancet.bsky.social
www.thelancet.com/journals/lan...
Was happy to talk about the current status of NSCLC ADC's after WCLC24! Looking forward to more advances in 2025! #lcsm #oncsky
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and ...
reachmd.com
January 2, 2025 at 7:35 PM
Important study and data in a patient group lacking strong next line options. Additionally notable with suggestion of CNS efficacy.
Also looking forward to approval and additional data on promising Patritumab Deruxtecan (HER3-DXd) in such a setting
Also looking forward to approval and additional data on promising Patritumab Deruxtecan (HER3-DXd) in such a setting
CHRYSALIS-2 Cohort A: amivantamab + lazertinib in #EGFR NSCLC after osimertinib and chemotherapy @jtoonline.bsky.social (n=162). BICR RR 35%, CBR 58%, DOR 8.3m, PFS 4.5m, OS 14.8m, and CNS efficacy noted. AEs included rash in 81% (G3 10%), paronychia in 52%.
www.jto.org/article/S155...
www.jto.org/article/S155...
www.jto.org
January 2, 2025 at 3:03 PM
Important study and data in a patient group lacking strong next line options. Additionally notable with suggestion of CNS efficacy.
Also looking forward to approval and additional data on promising Patritumab Deruxtecan (HER3-DXd) in such a setting
Also looking forward to approval and additional data on promising Patritumab Deruxtecan (HER3-DXd) in such a setting
Reposted by Laura Alder, MD
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
December 28, 2024 at 4:09 PM
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
Reposted by Laura Alder, MD
Details on uncommon #EGFR mutations @jtoonline.bsky.social. In 5212 #EGFR NSCLC dataset, 8.9% were uncommon mutations: associated with smoking history, higher rates of EGFR amp and TP53 co-mt, shorter time on TKI (4.1m) vs common (10.9m). #LCSM #OncSky
www.jto.org/article/S155...
www.jto.org/article/S155...
Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer.
Epidermal growth factor receptor (EGFR) mutations are key oncogenic drivers in lung adenocarcinoma (LUAD), predominantly affecting Asian, non-smoking, and female populations. While common mutations, such as exon 19 deletions and L858R, respond well to tyrosine kinase inhibitors (TKIs), uncommon EGFR mutations and compound variants exhibit variable treatment responses. This study aims to compare clinical characteristics and molecular profiles of patients with common, uncommon, and compound EGFR mutations, assessing their implications for therapy outcomes.
www.jto.org
December 17, 2024 at 2:06 PM
Details on uncommon #EGFR mutations @jtoonline.bsky.social. In 5212 #EGFR NSCLC dataset, 8.9% were uncommon mutations: associated with smoking history, higher rates of EGFR amp and TP53 co-mt, shorter time on TKI (4.1m) vs common (10.9m). #LCSM #OncSky
www.jto.org/article/S155...
www.jto.org/article/S155...
Reposted by Laura Alder, MD
Thoughtful commentary on perioperative immunotherapy for NSCLC from Drs. Tina Cascone and William William in Nature Reviews Clinical Oncology with their editorial on long-term data, durable benefit, and unanswered questions from the NADIM trial. #LCSM #OncSky
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer - Nature Reviews Clinical Oncology
As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes...
www.nature.com
December 13, 2024 at 12:43 PM
Thoughtful commentary on perioperative immunotherapy for NSCLC from Drs. Tina Cascone and William William in Nature Reviews Clinical Oncology with their editorial on long-term data, durable benefit, and unanswered questions from the NADIM trial. #LCSM #OncSky
www.nature.com/articles/s41...
www.nature.com/articles/s41...
So honored to be named Deputy Director of Duke Center for Brain and Spine Mets! CNS Mets in #lcsm is an area I’m passionate about, eager to collaborate with friends here #oncsky and continue to advance the field forward!!
@dukemedschool.bsky.social @dukeneurosurgery.bsky.social
@dukemedschool.bsky.social @dukeneurosurgery.bsky.social
December 12, 2024 at 10:21 AM
So honored to be named Deputy Director of Duke Center for Brain and Spine Mets! CNS Mets in #lcsm is an area I’m passionate about, eager to collaborate with friends here #oncsky and continue to advance the field forward!!
@dukemedschool.bsky.social @dukeneurosurgery.bsky.social
@dukemedschool.bsky.social @dukeneurosurgery.bsky.social
Reposted by Laura Alder, MD
We have known for decade+ that you can detect progression using ctDNA months before you see it on scans. But until we show that it impacts outcomes to change tx earlier all it does is make ppl anxious and abandon treatments (TKIs) that may still be helping. Most MRD use today is marketing over data.
Why aren’t more oncologists using MRD tests like Signatera or Guardant Reveal to proactively treat NSCLC before PD shows up on imaging especially in later treatment lines? www.jto.org/article/S155...
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and could be a dynamic indicator of treatment effect. This analysis aimed to determine whether longitudinal EGFR-mutation ctDNA testing could detect progressive disease (PD) before radiologic detection.
www.jto.org
December 8, 2024 at 1:06 PM
We have known for decade+ that you can detect progression using ctDNA months before you see it on scans. But until we show that it impacts outcomes to change tx earlier all it does is make ppl anxious and abandon treatments (TKIs) that may still be helping. Most MRD use today is marketing over data.
Reposted by Laura Alder, MD
Durvalumab now FDA approved for limited stage #SCLC based on the phase III ADRIATIC trial showing a PFS and an OS benefit (HR 0.73) with 2y of durvalumab after completion of definitive chemoradiation (avoid concurrent use). #LCSM #OncSky
www.targetedonc.com/view/durvalu....
www.targetedonc.com/view/durvalu....
Durvalumab Wins FDA Approval in Limited-Stage Small Cell Lung Cancer
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.
www.targetedonc.com
December 4, 2024 at 11:51 PM
Durvalumab now FDA approved for limited stage #SCLC based on the phase III ADRIATIC trial showing a PFS and an OS benefit (HR 0.73) with 2y of durvalumab after completion of definitive chemoradiation (avoid concurrent use). #LCSM #OncSky
www.targetedonc.com/view/durvalu....
www.targetedonc.com/view/durvalu....
Reposted by Laura Alder, MD
A must-read Review on the ever-evolving field of #EGFR mut #NSCLC in @natrevclinoncol.bsky.social highlighting:
➡️Strategies to improve on 1L 3rd Gen TKI mono therapy
➡️ Ways to tackle resistance post-Osi
➡️Perioperative landscape
@LeXiuning @danieltanmd @RamalingamMD @IASLC
#LCSM #some
➡️Strategies to improve on 1L 3rd Gen TKI mono therapy
➡️ Ways to tackle resistance post-Osi
➡️Perioperative landscape
@LeXiuning @danieltanmd @RamalingamMD @IASLC
#LCSM #some
December 1, 2024 at 8:50 PM
A must-read Review on the ever-evolving field of #EGFR mut #NSCLC in @natrevclinoncol.bsky.social highlighting:
➡️Strategies to improve on 1L 3rd Gen TKI mono therapy
➡️ Ways to tackle resistance post-Osi
➡️Perioperative landscape
@LeXiuning @danieltanmd @RamalingamMD @IASLC
#LCSM #some
➡️Strategies to improve on 1L 3rd Gen TKI mono therapy
➡️ Ways to tackle resistance post-Osi
➡️Perioperative landscape
@LeXiuning @danieltanmd @RamalingamMD @IASLC
#LCSM #some
Reposted by Laura Alder, MD
Great summary in @Annals_Oncology of an intensive few days in March 2024 discuss the key issues confronting lung cancer care globally, thanks to Dr. @mayluciemeyer for her excellent leadership on this manuscript! #lcsm @IASLC @myESMO
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Lung cancer research and treatment: global perspectives and strategic calls to action
Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to r…
www.sciencedirect.com
December 1, 2024 at 7:37 PM
Great summary in @Annals_Oncology of an intensive few days in March 2024 discuss the key issues confronting lung cancer care globally, thanks to Dr. @mayluciemeyer for her excellent leadership on this manuscript! #lcsm @IASLC @myESMO
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Reposted by Laura Alder, MD
Surgical resectability for locally advanced #LungCancer redefined -
Explore our expert consensus on who is eligible for curative #surgery in the age of #immunotherapy and targeted treatments.
From STS
#LCSM #SurgSky #MedSky #CancerSky
www.annalsthoracicsurgery.org/article/S000...
Explore our expert consensus on who is eligible for curative #surgery in the age of #immunotherapy and targeted treatments.
From STS
#LCSM #SurgSky #MedSky #CancerSky
www.annalsthoracicsurgery.org/article/S000...
November 29, 2024 at 4:52 PM
Surgical resectability for locally advanced #LungCancer redefined -
Explore our expert consensus on who is eligible for curative #surgery in the age of #immunotherapy and targeted treatments.
From STS
#LCSM #SurgSky #MedSky #CancerSky
www.annalsthoracicsurgery.org/article/S000...
Explore our expert consensus on who is eligible for curative #surgery in the age of #immunotherapy and targeted treatments.
From STS
#LCSM #SurgSky #MedSky #CancerSky
www.annalsthoracicsurgery.org/article/S000...
Intriguing paper utilizing unique DNA methylation signatures of LUAD brain metastases to predict risk and aid in noninvasive diagnosis via plasma. Many applications if prospectively validated: surveillance imaging timepoints, optimal treatment selection and timing.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Using tumor DNA methylomes to predict cancer metastasis to the brain - Nature Medicine
Metastatic spread of cancer to the brain has a devastating effect on patient outcomes, yet identifying patients who will develop brain metastases is difficult in current clinical practice. We show tha...
www.nature.com
November 27, 2024 at 9:26 PM
Intriguing paper utilizing unique DNA methylation signatures of LUAD brain metastases to predict risk and aid in noninvasive diagnosis via plasma. Many applications if prospectively validated: surveillance imaging timepoints, optimal treatment selection and timing.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Promising results in a patient population in huge need of improved treatment options and outcomes! Eager to see additional results #lcsm #oncsky
Dr Yang from NYU gives an Excellent talk on Proton CranioSpinal Radiation for LMD.
Best for high KPS, breast patients, low CTCs in CSF, stable extra cranial disease.
#bcsm
Best for high KPS, breast patients, low CTCs in CSF, stable extra cranial disease.
#bcsm
November 24, 2024 at 5:03 PM
76% 5 year OS, even with small numbers, represents such magnificent accomplishments in #LCSM! Taken with CROWN data (5 year PFS 60%, 92% pts free from intracranial progression!) helps cement Lorlatinib as clear 1st line choice for metastatic #lungcancer #oncsky @alkpositiveuk.bsky.social
Final survival results from phase II study of lorlatinib in #ALK NSCLC @jtoonline.bsky.social. In treatment naive (n=30), 5y OS 76%. Post 2nd gen ALK TKI ± chemo (n=28), 5y OS 45%, median OS 37.4m. Post ≥2 ALK TKIs ± chemo (n=111), 5y OS 23%, median OS 19.2m. #LCSM
www.jto.org/article/S155...
www.jto.org/article/S155...
Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study
Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of anaplastic
lymphoma kinase (ALK) and ROS1 tyrosine kinases with broad coverage of ALK resistance
mutations. We present overall su...
www.jto.org
November 24, 2024 at 12:50 AM
76% 5 year OS, even with small numbers, represents such magnificent accomplishments in #LCSM! Taken with CROWN data (5 year PFS 60%, 92% pts free from intracranial progression!) helps cement Lorlatinib as clear 1st line choice for metastatic #lungcancer #oncsky @alkpositiveuk.bsky.social
Honored to be interviewed about the rising incidence of lung cancer in non-smokers and especially females on @wral.bsky.social to shed light on #LCSM during #LungCancerAwarenessMonth and highlight the #HearHer campaign
www.wral.com/lifestyle/he...
@younglungcancer.bsky.social
www.wral.com/lifestyle/he...
@younglungcancer.bsky.social
Rising lung cancer cases in nonsmoking women under 50: Experts urge awareness
An unexpected surge in lung cancer cases among nonsmoking women under 50 is raising alarms among oncologists, emphasizing the need for heightened awareness.
www.wral.com
November 22, 2024 at 11:54 PM
Honored to be interviewed about the rising incidence of lung cancer in non-smokers and especially females on @wral.bsky.social to shed light on #LCSM during #LungCancerAwarenessMonth and highlight the #HearHer campaign
www.wral.com/lifestyle/he...
@younglungcancer.bsky.social
www.wral.com/lifestyle/he...
@younglungcancer.bsky.social
Reposted by Laura Alder, MD
Nice to see these guidelines on differentiating two primary lesions from metastatic disease in patients with NSCLC, an occasional diagnostic challenge. Big advance in past decade is using NGS www.jto.org/article/S155...
November 21, 2024 at 1:45 PM
Nice to see these guidelines on differentiating two primary lesions from metastatic disease in patients with NSCLC, an occasional diagnostic challenge. Big advance in past decade is using NGS www.jto.org/article/S155...
Reposted by Laura Alder, MD
Working on the #ASCO #SCLC guidelines, published in 2023, was disheartening, but working on the rapid update (based on #ASCO24 data) left me emotional.
This update represents hope & progress for patients who have waited far too long. ascopubs.org/doi/10.1200/...
#LCSM
This update represents hope & progress for patients who have waited far too long. ascopubs.org/doi/10.1200/...
#LCSM
Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update | Journal of Clinical Oncology
ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations
as a response to the emergence of new and practice-changing data. The rapid updates
are supported by an e...
ascopubs.org
November 21, 2024 at 1:53 AM
Working on the #ASCO #SCLC guidelines, published in 2023, was disheartening, but working on the rapid update (based on #ASCO24 data) left me emotional.
This update represents hope & progress for patients who have waited far too long. ascopubs.org/doi/10.1200/...
#LCSM
This update represents hope & progress for patients who have waited far too long. ascopubs.org/doi/10.1200/...
#LCSM